Eurofins Biomnis code

COLO1

Synonyms

• NGS
• oncologt
• targeted therapy
• solid tumor
• companion test

Clinic significance

The NGS "COLO1" panel fulfils the routine needs of clinicians for prescribing targeted therapies for metastatic colorectal cancer. The KRAS, NRAS and now also BRAF statuses can be used to guide the selection of a targeted therapy (monoclonal anti-EGFR Ab and anti-BRAF Ab). This panel is complemented by the MSI test, screening for MLH1 methylation and
COLO-RECTAL FISH unit tests.

Prenalytics

• Tumoral block included in paraffin or slides (6 slides 5µm) or DNA extract
• Ambient temperature

Further information

• Attach the anatomopathological report
• Use the specific request form B9-INTGB: Oncology-Solid tumors
• The use of the S25UK transport bag is Mandatory.

Specific equipment available

S25 : Envelope Genetics and Molecular Oncology

Documents to download

• Specific form (B9-INTGB)
• Management of solid tumours in Biopathology (DS5-INTGB)
• Digestive system Panel form (DS84-INTGB)

Methodology

Targeted sequencing of cancer genes (NGS) : -Library : AmpliSeq Library PLUS for Illumina Custom Panel V1 - Amplicon-based targeted library preparation method -NGS Platform : MiSeq Illumina - Flowcell : microV2 (2x150pb) - Paired-end reads -Analysis software : Miseq control Software version 2.6.2.1 /SeqOne Platform v1.2 - CE Pipeline version : SomaVar v1.4 CE -Limit of detection : 5% -Minimum depth accepted : 500x -Human genome version : Hg19

Turnaround time

10 days (Results may require an extended turnaround time, one week, depending on the confirmation tests required by Sanger sequencing)